← Back to patent-cliff list
Avenanthramide（Ceapro）
Tier C — Watch / tradeAvenanthramide（Ceapro）
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Updating
Indications (approved)：Inflammatory disease, 皮肤性疾病
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Avenanthramide（Ceapro）?
Approved indications include: Inflammatory disease, 皮肤性疾病.
When does the Avenanthramide（Ceapro） patent expire?
No public expiry year is available for Avenanthramide（Ceapro） yet; this page updates once verified.
How do I get a quote for Avenanthramide（Ceapro） intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03